AbbVie (ABBV) Rinvoq Gets FDA Nod for Active Psoriatic Arthritis

Posted byZacks Equity Research Leave a comment on AbbVie (ABBV) Rinvoq Gets FDA Nod for Active Psoriatic Arthritis

The FDA approves AbbVie’s (ABBV) Rinvoq for the treatment of adults with active psoriatic arthritis. This is the second FDA-approved indication for the drug.

Leave a comment

Your email address will not be published. Required fields are marked *